limit tamoxifen (Nolvadex) use to 5 years
January 1996
The National Cancer Institute is now alerting oncologists to limit tamoxifen (Nolvadex) use to 5 years...for certain women being treated for early-stage breast cancer.
This announcement refers specifically to women with node-negative, estrogen receptor-positive breast cancers.
Taking tamoxifen for 5 years after lumpectomy or mastectomy significantly reduces the risk of recurrence and improves survival.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote